Apixaban Dosing for DVT with Severe Renal Impairment

Initial Treatment Phase

The American College of Cardiology recommends starting with apixaban 10 mg orally twice daily for 7 days, then 5 mg twice daily for the remainder of the initial 3-month treatment period in patients with DVT and severe renal impairment, such as a creatinine clearance of 28 mL/min 1, 2
The dose reduction criteria for initial therapy, which includes age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, is not met in this patient, except for the renal criterion, which is insufficient for dose reduction during acute treatment 1

The European Society of Cardiology suggests that apixaban is the preferred DOAC in patients with severe renal impairment, as it should be avoided only when creatinine clearance is <15 mL/min 3, 2
A creatinine clearance of 28 mL/min falls in the "use with caution" zone but is not a contraindication to standard dosing for acute VTE treatment 3

The American College of Chest Physicians recommends using apixaban 2.5 mg twice daily rather than 5 mg twice daily for extended therapy in patients with severe renal impairment, such as a creatinine clearance of 28 mL/min 4, 5, 2
Extended anticoagulation is strongly recommended for unprovoked DVT or DVT with persistent risk factors, with no predefined stop date but should be reassessed at least annually 4, 5

The European Heart Journal recommends monitoring renal function periodically, as further deterioration below creatinine clearance 15 mL/min would contraindicate apixaban 3, 2
It is essential to avoid combining apixaban with antiplatelet agents, NSAIDs, or other anticoagulants, as this substantially increases bleeding risk 3
Checking for drug interactions with strong dual inhibitors of CYP3A4 and P-glycoprotein is crucial 1